Grudén et al, Int. Journal of Pharmaceutics (2021), Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse.
Klotz et al, European Urology Focus (2021) – Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients.
Grudén, Thesis for doctoral degree (Ph.D.) at Karolinska Institutet, Novel injectable calcium sulfate depot formulations for local cancer.
Grudén et al, Journal of Drug Delivery Science and Technology (2018) – Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations.
Tammela et al, The Journal of Urology, (2017) – An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Grundén et el, European Journal of Pharmaceutics and Biopharmaceutics (2017) – Antitumoral effect and reduced systemic toxicity in mice after intratumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel.
Sjögren et al, Molecular Pharmaceutics (2014) – Pharmacokinetics of an Injectable Modified Release Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model.
The International Society for Magnetic Resonance in Medicine (2018) – Magnetic resonance spectroscopy of localized prostate cancer: assessment of antitumor effects of intra-prostatic hormone deprivation therapy.
Annual Congress of the European Association of Urology (2016) – An open, single dose, anti-tumour effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot) injected into the prostate in patients with localized prostate cancer.
Annual Congress of the European Association of Urology (2014) – Local antiandrogen therapy, a novel treatment strategy for localized prostate cancer.
World Conference on Drug Absorption, Transport and Delivery (2013) – A semi-physiological biopharmaceutical model for simulation and prediction of 2-hydroxyflutamide concentrations in plasma and prostate tissue in prostate cancer patients following local administration of an injectable depot formulation.
Annual Congress of the European Association of Urology (2011) – Focal drug therapy, a novel treatment strategy for localized prostate cancer.